At 21.3x forward earnings with a PEG of 3, this is not a cheap stock relative to its growth profile, especially with an Altman Z-Score of 2.9 signaling only moderate balance sheet stability. The absence of a trailing P/E combined with a negative operating margin of -2.20% and ROIC of -0.30% suggests deteriorating profitability despite a $66,509M market cap that implies blue-chip expectations. A Piotroski F-Score of 4 reinforces that fundamentals are middling at best. This is a company priced for recovery while current returns and margins do not justify that optimism, creating a valuation disconnect skewed toward downside risk rather than mispricing opportunity.
